Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To Compare the Efficacy and Safety of Recombinant Human Vascular Endothelial Growth Factor Receptor Antibody Fusion Protein Eye Injection LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration wAMD : a Randomized, Double-blind, Parallel Controlled, Multicenter Clinical Trial

Next Previous
X
Search
Trial Profile

To Compare the Efficacy and Safety of Recombinant Human Vascular Endothelial Growth Factor Receptor Antibody Fusion Protein Eye Injection LY09004 and Eylea in the Treatment of Wet Age-related Macular Degeneration wAMD : a Randomized, Double-blind, Parallel Controlled, Multicenter Clinical Trial

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 16 Aug 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Sponsors Luye Pharma Group

    • Most Recent Events

    • 12 Aug 2024 According to an Ocumension Therapeutics, with positive results NDA for OT-702 has been submitted to and accepted by the CDE.
    • 12 Aug 2024 Status changed from active, no longer recruiting to completed.
    • 13 Mar 2023 According to a Luye Pharma Group media release, this clinical study is being conducted by Boan Biotech in collaboration with its partner Ocumension Therapeutics.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top